Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.
Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.
Stupp R, Taillibert S, Kanner A, et al.
2017;318(23):2306-2316.
Copyright 2017 American Medical Association. All rights reserved.
‘Out-of-the-box’ approach plus temozolomide extends survival in glioblastoma.
Goodman A.
http://www.ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma. Updated May 10, 2017. Accessed May 23, 2017.
Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multicenter, phase III trial.
Stupp R, Hegi ME, Idbaih A, et al.
2017; Abstract LBA AACR CT007.
Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.
Stupp R, Taillibert S, Kanner AA, et al.
2015;314(23):2535-2543.
Copyright 2015 American Medical Association. All rights reserved.
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
Stupp R, Wong ET, Kanner AA, et al.
2012;48(14):2192-2202.
Copyright 2012 Elsevier. All rights reserved.
Characterization and management of dermatologic adverse events with the NovoTTF‑100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Lacouture ME, Davis ME, Elzinga G, et al.
2014;41(3 suppl 4);S1-S14.
Copyright 2014 Elsevier Inc. All rights reserved.
NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study
Chaudhry A, Benson L, Varshaver M, et al.
2015;13:316. doi: 10.1186/s12957-015-0722-3.
Hear from Dr. Volker Stieber about unprecedented 5-year survival in newly diagnosed GBM.
View nowOPT-055.5-26
*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Contraindications
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.
Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.
Warnings and Precautions
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).
Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.
The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.
The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.
Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.
Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.
On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
* In 2015, SOC was considered surgery, radiation, and TMZ.4
† Median survival is shown as time from randomization. In the EORTC/NCIC study, patients were randomized within 6 weeks of diagnosis.2 In the EF-14 study, patients were randomized 4 to 6 weeks after chemoradiation, which was a median of 3.8 months from diagnosis.1
‡ In 2005, SOC was considered surgery and radiation.5
EORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada; OS, overall survival; SOC, standard of care; TMZ, temozolomide.
